Free Trial
→ Washington Is Broke—and Eyeing Your Savings Next (From Priority Gold) (Ad) Buy KALV Stock  Free KALV Stock Alerts

KalVista Pharmaceuticals (KALV) Financials

KalVista Pharmaceuticals logo
$11.87 -0.37 (-3.02%)
Closing price 04:00 PM Eastern
Extended Trading
$11.87 0.00 (0.00%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for KalVista Pharmaceuticals

Annual Income Statements for KalVista Pharmaceuticals

This table shows KalVista Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 4/30/2024 4/30/2023 4/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 -127 -93 -82
Consolidated Net Income / (Loss)		 -127 -93 -82
Net Income / (Loss) Continuing Operations		 -127 -93 -82
Total Pre-Tax Income 		-127 -93 -82
Total Operating Income		 -140 -111 -97
Total Gross Profit		 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00
Operating Revenue		 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00
Total Operating Expenses		 140 111 97
Selling, General & Admin Expense		 54 31 26
Research & Development Expense		 86 80 70
Total Other Income / (Expense), net		 14 18 14
Interest & Investment Income		 3.90 2.23 1.09
Other Income / (Expense), net		 9.91 16 13
Income Tax Expense		 0.00 0.00 0.00
Basic Earnings per Share		 ($3.44) ($3.33) ($3.36)
Weighted Average Basic Shares Outstanding		 36.79M 27.89M 24.47M
Diluted Earnings per Share		 ($3.44) ($3.33) ($3.36)
Weighted Average Diluted Shares Outstanding		 36.79M 27.89M 24.47M
Weighted Average Basic & Diluted Shares Outstanding		 42.74M 34.23M 24.57M

Quarterly Income Statements for KalVista Pharmaceuticals

This table shows KalVista Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023
Period end date 1/31/2025 10/31/2024 7/31/2024 4/30/2024 1/31/2024 10/31/2023 7/31/2023 4/30/2023 1/31/2023 10/31/2022 7/31/2022
Net Income / (Loss) Attributable to Common Shareholders		 -49 -42 -40 -45 -29 -28 -25 -26 -21 -22 -23
Consolidated Net Income / (Loss)		 -49 -42 -40 -45 -29 -28 -25 -26 -21 -22 -23
Net Income / (Loss) Continuing Operations		 -49 -42 -40 -45 -29 -28 -25 -26 -21 -22 -23
Total Pre-Tax Income 		-44 -42 -40 -45 -29 -28 -25 -26 -21 -22 -23
Total Operating Income		 -43 -46 -44 -48 -33 -30 -29 -32 -27 -26 -26
Total Gross Profit		 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Operating Revenue		 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses		 43 46 44 48 33 30 29 32 27 26 26
Selling, General & Admin Expense		 30 29 18 23 11 11 9.79 7.78 6.88 7.81 8.13
Research & Development Expense		 13 17 27 25 23 19 19 24 20 18 18
Total Other Income / (Expense), net		 -1.32 3.54 3.77 3.81 4.12 2.10 3.78 5.42 5.64 3.63 3.27
Interest Expense		 2.84 - - - 0.00 - - - - - -
Interest & Investment Income		 1.39 1.36 1.69 1.51 0.68 0.78 0.92 0.81 0.73 0.45 0.24
Other Income / (Expense), net		 0.13 2.19 2.08 2.29 3.44 1.32 2.85 4.61 4.91 3.18 3.03
Income Tax Expense		 4.25 - - - 0.00 - - - - - -
Basic Earnings per Share		 ($0.92) ($0.91) ($0.87) ($1.06) ($0.84) ($0.80) ($0.74) ($0.74) ($0.75) ($0.90) ($0.94)
Weighted Average Basic Shares Outstanding		 52.64M 46.70M 46.23M 36.79M 34.72M 34.57M 34.41M 27.89M 28.28M 24.60M 24.56M
Diluted Earnings per Share		 ($0.92) ($0.91) ($0.87) ($1.06) ($0.84) ($0.80) ($0.74) ($0.74) ($0.75) ($0.90) ($0.94)
Weighted Average Diluted Shares Outstanding		 52.64M 46.70M 46.23M 36.79M 34.72M 34.57M 34.41M 27.89M 28.28M 24.60M 24.56M
Weighted Average Basic & Diluted Shares Outstanding		 49.72M 49.42M 43.22M 42.74M 42.19M 34.56M 34.40M 34.23M 34.17M 24.62M 24.60M

Annual Cash Flow Statements for KalVista Pharmaceuticals

This table details how cash moves in and out of KalVista Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 4/30/2024 4/30/2023 4/30/2022
Net Change in Cash & Equivalents		 -24 26 -20
Net Cash From Operating Activities		 -89 -75 -78
Net Cash From Continuing Operating Activities		 -89 -75 -79
Net Income / (Loss) Continuing Operations		 -127 -93 -82
Consolidated Net Income / (Loss)		 -127 -93 -82
Depreciation Expense		 0.82 0.72 0.56
Amortization Expense		 0.09 0.99 2.57
Non-Cash Adjustments To Reconcile Net Income		 30 6.21 13
Changes in Operating Assets and Liabilities, net		 6.99 9.73 -12
Net Cash From Investing Activities		 -85 41 58
Net Cash From Continuing Investing Activities		 -85 41 58
Purchase of Property, Plant & Equipment		 -0.44 -1.20 -0.93
Purchase of Investments		 -189 -98 -137
Sale and/or Maturity of Investments		 105 141 196
Net Cash From Financing Activities		 151 58 1.58
Net Cash From Continuing Financing Activities		 151 58 1.58
Issuance of Common Equity		 151 58 1.58
Effect of Exchange Rate Changes		 -1.21 1.24 -1.17

Quarterly Cash Flow Statements for KalVista Pharmaceuticals

This table details how cash moves in and out of KalVista Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023
Period end date 1/31/2025 10/31/2024 7/31/2024 4/30/2024 1/31/2024 10/31/2023 7/31/2023 4/30/2023 1/31/2023 10/31/2022 7/31/2022
Net Change in Cash & Equivalents		 126 9.73 0.06 8.73 -35 8.26 -6.83 -29 46 0.72 7.13
Net Cash From Operating Activities		 -33 -40 -40 -15 -28 -20 -27 -23 -9.29 -21 -23
Net Cash From Continuing Operating Activities		 -33 -40 -40 -15 -28 -20 -27 -23 -9.29 -21 -23
Net Income / (Loss) Continuing Operations		 -49 -42 -40 -45 -29 -28 -25 -26 -21 -22 -23
Consolidated Net Income / (Loss)		 -49 -42 -40 -45 -29 -28 -25 -26 -21 -22 -23
Depreciation Expense		 0.23 0.23 0.22 0.22 0.21 0.20 0.19 0.19 0.20 0.17 0.16
Amortization Expense		 2.93 0.01 0.01 0.00 0.01 0.02 0.06 0.10 0.21 0.29 0.39
Non-Cash Adjustments To Reconcile Net Income		 7.92 2.18 2.30 27 0.17 -0.31 2.55 -2.12 3.79 1.43 3.11
Changes in Operating Assets and Liabilities, net		 4.76 0.21 -2.31 2.22 1.07 7.92 -4.22 5.50 7.81 -0.23 -3.36
Net Cash From Investing Activities		 8.52 49 37 -126 -6.70 29 20 -6.21 -2.52 20 30
Net Cash From Continuing Investing Activities		 8.52 49 37 -126 -6.70 29 20 -6.21 -2.52 20 30
Purchase of Property, Plant & Equipment		 -0.13 -0.20 -0.09 -0.12 -0.11 -0.21 -0.01 -0.07 -0.02 -0.19 -0.92
Purchase of Investments		 -6.56 -0.00 -0.98 -142 -18 -3.77 -26 -34 -54 - -10
Sale and/or Maturity of Investments		 15 49 38 15 12 33 45 28 51 20 41
Net Cash From Financing Activities		 152 0.30 3.00 150 0.28 0.13 0.20 -0.03 58 0.17 0.17
Net Cash From Continuing Financing Activities		 152 0.30 3.00 150 0.28 0.13 0.20 -0.03 58 0.17 0.17
Issuance of Common Equity		 57 0.30 3.00 150 0.28 0.13 0.20 -0.03 58 0.17 0.17
Effect of Exchange Rate Changes		 -1.25 0.41 0.12 -0.07 -0.62 -0.60 0.08 0.07 0.46 1.05 -0.34

Annual Balance Sheets for KalVista Pharmaceuticals

This table presents KalVista Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 4/30/2024 4/30/2023 4/30/2022
Total Assets		 235 183 204
Total Current Assets		 226 172 194
Cash & Equivalents		 32 56 31
Short-Term Investments		 179 93 135
Prepaid Expenses		 6.85 6.38 13
Other Current Assets		 8.44 17 14
Plant, Property, & Equipment, net		 2.23 2.95 2.18
Total Noncurrent Assets		 7.49 7.93 8.06
Other Noncurrent Operating Assets		 7.49 7.93 8.06
Total Liabilities & Shareholders' Equity		 235 183 204
Total Liabilities		 29 22 19
Total Current Liabilities		 23 15 12
Accounts Payable		 9.11 4.82 3.64
Accrued Expenses		 12 9.13 6.96
Other Current Liabilities		 1.30 1.09 0.98
Total Noncurrent Liabilities		 6.02 7.15 7.21
Capital Lease Obligations		 6.02 - -
Other Noncurrent Operating Liabilities		 0.00 7.15 7.21
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 207 161 185
Total Preferred & Common Equity		 207 161 185
Total Common Equity		 207 161 185
Common Stock		 680 507 439
Retained Earnings		 -470 -343 -250
Accumulated Other Comprehensive Income / (Loss)		 -3.49 -3.06 -3.86

Quarterly Balance Sheets for KalVista Pharmaceuticals

This table presents KalVista Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2025 Q2 2025 Q1 2025 Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023
Period end date 1/31/2025 10/31/2024 7/31/2024 1/31/2024 10/31/2023 7/31/2023 1/31/2023 10/31/2022 7/31/2022
Total Assets		 276 161 200 114 139 160 203 163 182
Total Current Assets		 267 152 192 104 129 150 192 151 170
Cash & Equivalents		 167 42 32 23 58 49 85 39 38
Short-Term Investments		 86 94 142 53 46 74 87 84 104
Prepaid Expenses		 6.67 5.41 7.45 5.51 5.46 7.53 8.56 8.91 11
Other Current Assets		 7.49 11 9.91 23 20 19 12 20 17
Plant, Property, & Equipment, net		 1.81 2.04 2.10 2.42 2.50 2.81 3.04 3.06 3.03
Total Noncurrent Assets		 6.83 6.53 6.46 7.44 7.64 7.68 8.30 8.56 8.88
Other Noncurrent Operating Assets		 6.83 6.53 6.46 7.44 7.64 7.68 8.30 8.56 8.88
Total Liabilities & Shareholders' Equity		 276 161 200 114 139 160 203 163 182
Total Liabilities		 131 27 27 25 24 21 19 19 18
Total Current Liabilities		 26 22 22 19 18 14 12 11 9.73
Accounts Payable		 5.86 5.20 11 3.10 4.90 5.06 1.70 3.38 2.91
Accrued Expenses		 18 15 10 15 12 7.95 8.85 6.91 5.83
Other Current Liabilities		 1.44 1.54 1.26 1.19 1.15 1.12 1.06 1.03 1.00
Total Noncurrent Liabilities		 105 4.68 4.99 6.26 6.55 6.87 7.42 7.71 8.01
Capital Lease Obligations		 4.34 4.68 - - - - - - -
Other Noncurrent Operating Liabilities		 101 - 4.99 6.26 6.55 6.87 7.42 7.71 8.01
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 145 134 173 89 114 139 184 144 165
Total Preferred & Common Equity		 145 134 173 89 114 139 184 144 165
Total Common Equity		 145 134 173 89 114 139 184 144 165
Common Stock		 748 689 686 517 514 511 505 445 442
Retained Earnings		 -601 -552 -510 -425 -396 -368 -317 -295 -273
Accumulated Other Comprehensive Income / (Loss)		 -2.21 -2.70 -2.87 -3.29 -3.47 -2.89 -3.54 -5.33 -4.15

Annual Metrics And Ratios for KalVista Pharmaceuticals

This table displays calculated financial ratios and metrics derived from KalVista Pharmaceuticals' official financial filings.

Metric 2024 2023 2022
Period end date 4/30/2024 4/30/2023 4/30/2022
Growth Metrics		 - - -
Revenue Growth		 0.00% 0.00% 0.00%
EBITDA Growth		 -38.74% -16.35% -68.63%
EBIT Growth		 -37.21% -14.04% -70.82%
NOPAT Growth		 -26.67% -14.76% -66.80%
Net Income Growth		 -36.31% -12.83% -78.05%
EPS Growth		 -3.30% 0.89% -38.84%
Operating Cash Flow Growth		 -18.56% 3.68% -158.97%
Free Cash Flow Firm Growth		 -17.73% 10.08% -138.79%
Invested Capital Growth		 -132.78% -38.33% 128.59%
Revenue Q/Q Growth		 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -17.29% -3.42% -10.08%
EBIT Q/Q Growth		 -17.08% -2.96% -9.76%
NOPAT Q/Q Growth		 -13.52% -4.64% -9.98%
Net Income Q/Q Growth		 -16.94% -2.42% -12.51%
EPS Q/Q Growth		 -10.26% 6.72% -10.16%
Operating Cash Flow Q/Q Growth		 7.78% 5.23% -25.23%
Free Cash Flow Firm Q/Q Growth		 4.61% 4.62% -17.88%
Invested Capital Q/Q Growth		 -129.38% -8.67% 43.69%
Profitability Metrics		 - - -
Gross Margin		 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00%
Interest Burden Percent		 97.02% 97.65% 98.69%
Effective Tax Rate		 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -68.90% -53.69% -37.23%
Cash Return on Invested Capital (CROIC)		 0.00% -460.81% -576.37%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -68.90% -53.69% -37.23%
Return on Equity Simple (ROE_SIMPLE)		 -61.30% -57.70% -44.49%
Net Operating Profit after Tax (NOPAT)		 -98 -78 -68
NOPAT Margin		 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -15.75% -9.69% -7.09%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -131 -95 -83
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -130 -93 -80
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 2.32 1.81 1.69
Price to Tangible Book Value (P/TBV)		 2.32 1.81 1.69
Price to Revenue (P/Rev)		 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 12.20 7.74
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00
Leverage & Solvency		 - - -
Debt to Equity		 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00
Financial Leverage		 -0.98 -0.91 -0.94
Leverage Ratio		 1.14 1.12 1.08
Compound Leverage Factor		 1.10 1.09 1.06
Debt to Total Capital		 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00
Altman Z-Score		 6.38 4.58 7.98
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00%
Liquidity Ratios		 - - -
Current Ratio		 9.90 11.46 16.73
Quick Ratio		 9.23 9.94 14.36
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 -83 -70 -78
Operating Cash Flow to CapEx		 -20,142.44% -6,292.73% -8,392.48%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00
Efficiency Ratios		 - - -
Asset Turnover		 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00
Capital & Investment Metrics		 - - -
Invested Capital		 -3.82 12 19
Invested Capital Turnover		 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -15 -7.24 11
Enterprise Value (EV)		 268 142 146
Market Capitalization		 479 291 312
Book Value per Share		 $4.90 $4.71 $7.54
Tangible Book Value per Share		 $4.90 $4.71 $7.54
Total Capital		 207 161 185
Total Debt		 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00
Net Debt		 -210 -149 -166
Capital Expenditures (CapEx)		 0.44 1.20 0.93
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -7.52 7.92 16
Debt-free Net Working Capital (DFNWC)		 203 157 182
Net Working Capital (NWC)		 203 157 182
Net Nonoperating Expense (NNE)		 28 15 15
Net Nonoperating Obligations (NNO)		 -210 -149 -166
Total Depreciation and Amortization (D&A)		 0.91 1.71 3.13
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 ($3.44) ($3.33) ($3.36)
Adjusted Weighted Average Basic Shares Outstanding		 36.79M 27.89M 24.47M
Adjusted Diluted Earnings per Share		 ($3.44) ($3.33) ($3.36)
Adjusted Weighted Average Diluted Shares Outstanding		 36.79M 27.89M 24.47M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 42.74M 34.23M 24.57M
Normalized Net Operating Profit after Tax (NOPAT)		 -98 -78 -68
Normalized NOPAT Margin		 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00
Payout Ratios		 - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for KalVista Pharmaceuticals

This table displays calculated financial ratios and metrics derived from KalVista Pharmaceuticals' official financial filings.

Metric Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023
Period end date 1/31/2025 10/31/2024 7/31/2024 4/30/2024 1/31/2024 10/31/2023 7/31/2023 4/30/2023 1/31/2023 10/31/2022 7/31/2022
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -34.44% -53.83% -61.27% -71.24% -36.42% -26.80% -14.30% -13.00% 1.35% -16.22% -46.70%
EBIT Growth		 -44.10% -53.47% -60.58% -70.25% -34.84% -25.19% -12.70% -11.21% 3.04% -13.87% -42.12%
NOPAT Growth		 -29.53% -54.01% -51.98% -52.72% -23.03% -14.92% -10.55% -18.34% -0.98% -9.66% -34.84%
Net Income Growth		 -67.11% -52.87% -59.75% -69.74% -36.26% -24.23% -9.87% -9.09% 5.18% -13.27% -43.04%
EPS Growth		 -9.52% -13.75% -17.57% -43.24% -12.00% 11.11% 21.28% 24.49% 18.48% -12.50% -42.42%
Operating Cash Flow Growth		 -18.53% -99.96% -50.47% 33.27% -196.81% 3.73% -17.54% 15.50% 33.96% -5.37% -28.23%
Free Cash Flow Firm Growth		 469.68% -124.37% 3.92% -23.26% -26.94% 52.02% 48.57% 49.08% 21.64% 8.88% -56.25%
Invested Capital Growth		 -898.18% -74.36% -109.16% -132.78% 1.89% -47.66% -28.53% -38.33% -2.97% 21.98% 63.03%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 8.60% -3.55% 8.78% -55.73% -4.58% -8.55% 3.14% -24.07% 2.80% 2.15% 4.24%
EBIT Q/Q Growth		 1.86% -3.54% 8.72% -55.36% -4.52% -8.33% 3.22% -23.05% 2.96% 2.48% 4.50%
NOPAT Q/Q Growth		 6.27% -3.61% 8.75% -46.16% -11.45% -2.24% 8.30% -17.75% -4.10% 1.65% 1.85%
Net Income Q/Q Growth		 -14.77% -4.51% 9.42% -53.81% -4.98% -9.22% 3.76% -23.48% 4.29% 3.41% 4.44%
EPS Q/Q Growth		 -1.10% -4.60% 17.92% -26.19% -5.00% -8.11% 0.00% 1.33% 16.67% 4.26% 4.08%
Operating Cash Flow Q/Q Growth		 17.56% 1.44% -166.27% 45.21% -39.07% 25.83% -18.09% -143.69% 54.89% 9.45% 15.11%
Free Cash Flow Firm Q/Q Growth		 465.97% -76.76% 27.37% 21.31% -122.11% 24.31% 6.83% 18.96% 16.04% 18.88% 7.74%
Invested Capital Q/Q Growth		 -3,688.34% 296.27% 61.43% -129.38% 15.28% -29.88% 38.01% -8.67% -40.78% -4.25% 19.09%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 109.60% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 103.38% 96.89% 95.98% 96.72% 97.70% 97.27% 96.48% 97.02% 96.68% 98.02% 98.96%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -150.50% -125.90% -90.84% -68.90% -79.33% -77.89% -62.64% -53.69% -46.24% -49.49% -43.65%
Cash Return on Invested Capital (CROIC)		 0.00% -1,577.97% 0.00% 0.00% -674.43% -438.79% -379.18% -460.81% -569.64% -397.29% -446.81%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -150.50% -125.90% -90.84% -68.90% -79.33% -77.89% -62.64% -53.69% -46.24% -49.49% -43.65%
Return on Equity Simple (ROE_SIMPLE)		 -121.18% -116.71% -82.04% 0.00% -122.26% -87.88% -68.31% 0.00% -49.18% -63.89% -54.25%
Net Operating Profit after Tax (NOPAT)		 -30 -32 -31 -34 -23 -21 -20 -22 -19 -18 -18
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -11.37% -8.71% -6.38% -5.97% -4.71% -6.06% -3.73% -2.60% -1.33% -2.49% -2.48%
Return On Investment Capital (ROIC_SIMPLE)		 -20.11% - - - -26.20% - - - - - -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -43 -44 -42 -46 -30 -28 -26 -27 -22 -23 -23
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -40 -43 -42 -46 -30 -28 -26 -27 -22 -22 -23
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.03 3.31 3.60 2.32 6.15 2.55 2.48 1.81 1.06 0.87 1.84
Price to Tangible Book Value (P/TBV)		 3.03 3.31 3.60 2.32 6.15 2.55 2.48 1.81 1.06 0.87 1.84
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 108.17 0.00 0.00 36.12 16.76 13.84 12.20 1.90 0.11 7.17
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.03 0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.03 0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.39 -0.94 -0.95 -0.98 -0.91 -0.87 -0.87 -0.91 -0.93 -0.89 -0.91
Leverage Ratio		 1.67 1.21 1.16 1.14 1.16 1.17 1.13 1.12 1.09 1.10 1.08
Compound Leverage Factor		 1.73 1.17 1.11 1.10 1.14 1.14 1.09 1.09 1.06 1.07 1.07
Debt to Total Capital		 2.90% 3.37% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 2.90% 3.37% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 97.10% 96.63% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 -0.03 -0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 1.46 0.82 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 -0.03 -0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.03 -0.04 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 1.96 1.09 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 -0.03 -0.04 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -0.49 5.19 10.36 7.56 7.69 3.50 7.14 5.81 4.71 1.96 8.80
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 10.44 6.87 8.55 9.90 5.44 7.25 10.60 11.46 16.55 13.36 17.51
Quick Ratio		 9.89 6.13 7.78 9.23 3.95 5.81 8.72 9.94 14.79 10.80 14.60
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 87 -24 -13 -18 -23 -11 -14 -15 -18 -22 -27
Operating Cash Flow to CapEx		 -25,733.07% -19,624.75% -47,317.65% -12,381.15% -25,064.55% -9,670.73% -445,500.00% -32,805.80% -61,926.67% -10,726.04% -2,471.96%
Free Cash Flow to Firm to Interest Expense		 30.50 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -11.50 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -11.54 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -104 2.89 -1.47 -3.82 13 11 16 12 13 22 22
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -117 -8.38 -18 -15 0.24 -10 -6.42 -7.24 -0.39 3.88 8.70
Enterprise Value (EV)		 191 313 447 268 469 189 223 142 24 2.46 161
Market Capitalization		 440 444 621 479 545 292 346 291 196 125 303
Book Value per Share		 $2.94 $3.10 $4.04 $4.90 $2.56 $3.33 $4.07 $4.71 $7.49 $5.85 $6.70
Tangible Book Value per Share		 $2.94 $3.10 $4.04 $4.90 $2.56 $3.33 $4.07 $4.71 $7.49 $5.85 $6.70
Total Capital		 149 139 173 207 89 114 139 161 184 144 165
Total Debt		 4.34 4.68 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 4.34 4.68 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -249 -131 -174 -210 -76 -103 -123 -149 -172 -122 -142
Capital Expenditures (CapEx)		 0.13 0.20 0.09 0.12 0.11 0.21 0.01 0.07 0.02 0.19 0.92
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -11 -5.67 -5.05 -7.52 9.39 7.68 12 7.92 8.84 18 19
Debt-free Net Working Capital (DFNWC)		 242 130 169 203 85 111 136 157 181 140 161
Net Working Capital (NWC)		 242 130 169 203 85 111 136 157 181 140 161
Net Nonoperating Expense (NNE)		 18 10 9.49 11 5.82 6.83 4.95 4.10 2.44 4.14 4.62
Net Nonoperating Obligations (NNO)		 -249 -131 -174 -210 -76 -103 -123 -149 -172 -122 -142
Total Depreciation and Amortization (D&A)		 3.15 0.23 0.23 0.22 0.21 0.22 0.26 0.29 0.41 0.46 0.55
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.92) ($0.91) ($0.87) ($1.06) ($0.84) ($0.80) ($0.74) ($0.74) ($0.75) ($0.90) ($0.94)
Adjusted Weighted Average Basic Shares Outstanding		 52.64M 46.70M 46.23M 36.79M 34.72M 34.57M 34.41M 27.89M 28.28M 24.60M 24.56M
Adjusted Diluted Earnings per Share		 ($0.92) ($0.91) ($0.87) ($1.06) ($0.84) ($0.80) ($0.74) ($0.74) ($0.75) ($0.90) ($0.94)
Adjusted Weighted Average Diluted Shares Outstanding		 52.64M 46.70M 46.23M 36.79M 34.72M 34.57M 34.41M 27.89M 28.28M 24.60M 24.56M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 49.72M 49.42M 43.22M 42.74M 42.19M 34.56M 34.40M 34.23M 34.17M 24.62M 24.60M
Normalized Net Operating Profit after Tax (NOPAT)		 -30 -32 -31 -34 -23 -21 -20 -22 -19 -18 -18
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -15.06 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -10.58 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -15.11 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -10.62 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About KalVista Pharmaceuticals' Financials

When does KalVista Pharmaceuticals's fiscal year end?

According to the most recent income statement we have on file, KalVista Pharmaceuticals' financial year ends in April. Their financial year 2024 ended on April 30, 2024.

How has KalVista Pharmaceuticals' net income changed over the last 2 years?

KalVista Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$126.64 million in 2024, rising from -$82.34 million in 2022. The previous period was -$92.91 million in 2023. See KalVista Pharmaceuticals' forecast for analyst expectations on what’s next for the company.

What is KalVista Pharmaceuticals's operating income?
KalVista Pharmaceuticals's total operating income in 2024 was -$140.45 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $140.45 million
How has KalVista Pharmaceuticals revenue changed over the last 2 years?

Over the last 2 years, KalVista Pharmaceuticals' total revenue changed from $0.00 in 2022 to $0.00 in 2024, a change of 0.0%.

How much debt does KalVista Pharmaceuticals have?

KalVista Pharmaceuticals' total liabilities were at $28.82 million at the end of 2024, a 30.0% increase from 2023, and a 53.4% increase since 2022.

How much cash does KalVista Pharmaceuticals have?

In the past 2 years, KalVista Pharmaceuticals' cash and equivalents has ranged from $30.73 million in 2022 to $56.24 million in 2023, and is currently $31.79 million as of their latest financial filing in 2024.

How has KalVista Pharmaceuticals' book value per share changed over the last 2 years?

Over the last 2 years, KalVista Pharmaceuticals' book value per share changed from 7.54 in 2022 to 4.90 in 2024, a change of -35.1%.


Related Companies

This page (NASDAQ:KALV) was last updated on 5/21/2025 by MarketBeat.com Staff
From Our Partners
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...
Porter & Company | Sponsored
Elon Set to Shock the World on June 1st?
Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...
Brownstone Research | Sponsored
Man who predicted $100K Bitcoin sees a huge run coming for another coin …
Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...
Weiss Ratings | Sponsored
Massive new energy source found in Utah
NEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...
Stansberry Research | Sponsored
July 2025 Rule Change to Impact Retirement Investors
There's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...
Premier Gold Co | Sponsored
Why Elon put $51 million into this
Why Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT Scientists
True Market Insiders | Sponsored
3..2..1.. AI 2.0 ignition (don’t sleep on this)
I just put together an urgent new presentation that you need to see right away. In short: I believe we are...
Timothy Sykes | Sponsored